Why early pathology input matters in biologically rich cancer trials
Open Access
- 1 September 2026
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- p. 1-4
Abstract
Pathology is central to many biologically driven cancer clinical trials. Biomarker-led and translational studies depend on robust tissue pathways, cellular and molecular assays, pathology-derived endpoints, and clinically meaningful interpretation of discovery science. Where trials depend on tumour material, biomarker-defined eligibility or mechanism-focused endpoints, pathology expertise should be embedded early, before protocols, budgets, and assays are fixed. Early pathology input strengthens feasibility, specimen governance, assay selection, quality assurance, and the long-term value of collected samples. In the UK, the Clinical Trials Pathology Advisory Group, now within the new Pathological Society of Great Britain and Ireland Clinical Trials Pathology subcommittee, provides a practical route for pre-submission specialist review. This Perspective argues that pathology is core infrastructure for biologically rich trials, linking discovery science to clinical translation.Keywords
Funding Information
- Cancer Research UK (CTRQQR-2021\100006)
- Cancer Research UK (CTRQQR-2021\100006)
This publication has 19 references indexed in Scilit:
- The role of the pathologist in the design and conducting of biomarker-driven clinical trials in cancer: position paper of the European Society of PathologyVirchows Archiv, 2024
- Assessment of clinical trial protocols for pathology content using the SPIRIT‐Path guidelines highlights areas for improvementThe Journal of Pathology: Clinical Research, 2022
- Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extensionThe Lancet Oncology, 2021
- Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta‐aggregationThe Journal of Pathology: Clinical Research, 2021
- The National Lung Matrix Trial of personalized therapy in lung cancerNature, 2020
- The use of digital pathology and image analysis in clinical trialsThe Journal of Pathology: Clinical Research, 2019
- Training and accreditation standards for pathologists undertaking clinical trial workThe Journal of Pathology: Clinical Research, 2019
- Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial workThe Journal of Pathology: Clinical Research, 2018
- Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis TrialLaboratory Investigation, 2017
- Pathology is a necessary and informative tool in oncology clinical trialsThe Journal of Pathology, 2013